Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Yale University
With
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Augusta University
Penn State University
University of California, San Francisco
University of North Carolina
University of Oklahoma
University of Pennsylvania
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Female with a persisting pregnancy of unknown location:
A pregnancy of unknown location is defined as a pregnancy in a woman with a positive pregnancy test but no definitive signs of pregnancy in the uterus or adnexa on ultrasound imaging. A definitive sign of gestation includes ultrasound visualization of a gestational sac with a yolk sac (with or without an embryo) in the uterus or in the adnexa. Ultrasound must be performed within 7 days prior to randomization.
Persistence of hCG is defined as at least 2 serial hCG values (over 2-14 days), showing \< 15% rise per day, or \< 50% fall between the first and last value.
Patient is hemodynamically stable, hemoglobin \>10 mg/dL
Greater than or 18 years of age
You may not be if
Hemodynamically unstable in need of acute treatment
Most recent hCG \> 5000 mIU/mL
Patient obtaining care in relation to a recently completed pregnancy (delivery, spontaneous or elective abortion)
Diagnosis of gestational trophoblastic disease
Subject unwilling or unable to comply with study procedures
Known hypersensitivity to MTX
Presence of clinical contraindications for treatment with MTX
Prior medical or surgical management of this gestation
Subject unwilling to accept a blood transfusion
Clareo Health | Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location
